US5849263A
(en)
*
|
1993-03-30 |
1998-12-15 |
Charlotte-Mecklenburg Hospital Authority |
Pharmaceutical compositions containing alkylaryl polyether alcohol polymer
|
US5576311A
(en)
*
|
1994-11-30 |
1996-11-19 |
Pharmos Corporation |
Cyclodextrins as suspending agents for pharmaceutical suspensions
|
US5976573A
(en)
*
|
1996-07-03 |
1999-11-02 |
Rorer Pharmaceutical Products Inc. |
Aqueous-based pharmaceutical composition
|
US5800832A
(en)
*
|
1996-10-18 |
1998-09-01 |
Virotex Corporation |
Bioerodable film for delivery of pharmaceutical compounds to mucosal surfaces
|
US5955097A
(en)
*
|
1996-10-18 |
1999-09-21 |
Virotex Corporation |
Pharmaceutical preparation applicable to mucosal surfaces and body tissues
|
TW503113B
(en)
*
|
1997-01-16 |
2002-09-21 |
Senju Pharma Co |
Aqueous suspension for nasal administration
|
KR100508227B1
(ko)
*
|
1997-03-14 |
2006-03-23 |
센주 세이야꾸 가부시키가이샤 |
로테프레드놀에타보네이트수성현탁액
|
US20050048102A1
(en)
*
|
1997-10-16 |
2005-03-03 |
Virotex Corporation |
Pharmaceutical carrier device suitable for delivery of pharmaceutical compounds to mucosal surfaces
|
SE9704186D0
(sv)
*
|
1997-11-14 |
1997-11-14 |
Astra Ab |
New composition of matter
|
WO1999037286A1
(fr)
*
|
1998-01-22 |
1999-07-29 |
Santen Pharmaceutical Co., Ltd. |
Collyre a suspension de fluorometholone
|
US6103266A
(en)
*
|
1998-04-22 |
2000-08-15 |
Tapolsky; Gilles H. |
Pharmaceutical gel preparation applicable to mucosal surfaces and body tissues
|
CA2342797A1
(en)
*
|
1998-09-02 |
2000-03-09 |
Allergan Sales, Inc. |
Preserved cyclodextrin-containing compositions
|
US6395746B1
(en)
|
1998-09-30 |
2002-05-28 |
Alcon Manufacturing, Ltd. |
Methods of treating ophthalmic, otic and nasal infections and attendant inflammation
|
US6716830B2
(en)
|
1998-09-30 |
2004-04-06 |
Alcon, Inc. |
Ophthalmic antibiotic compositions containing moxifloxacin
|
US6509327B1
(en)
|
1998-09-30 |
2003-01-21 |
Alcon Manufacturing, Ltd. |
Compositions and methods for treating otic, ophthalmic and nasal infections
|
WO2000078297A2
(de)
*
|
1999-06-22 |
2000-12-28 |
Boehringer Ingelheim International Gmbh |
Stabile xylometazolin- und oxymetazolinlösung
|
FR2796553B1
(fr)
*
|
1999-07-22 |
2001-09-28 |
Warner Lambert Co |
Suspension de tixocortol pivalate, collutoire a base de celle-ci et conditionnement la contenant
|
KR100722502B1
(ko)
|
1999-09-24 |
2007-05-28 |
알콘, 인코퍼레이티드 |
사이프로플록사신 및 덱사메타손 함유 국소용 현탁제
|
AU7947600A
(en)
*
|
1999-10-20 |
2001-04-30 |
Teijin Limited |
Aqueous medicinal compositions
|
AR026073A1
(es)
|
1999-10-20 |
2002-12-26 |
Nycomed Gmbh |
Composicion farmaceutica acuosa que contiene ciclesonida
|
EP1242090A4
(de)
*
|
1999-11-18 |
2004-02-11 |
Alcon Inc |
Verwendung eines h1-antagonisten und eines sicheren steroids zur behandlung von augenerkrankungen
|
US20040097486A1
(en)
*
|
1999-11-18 |
2004-05-20 |
Yanni John M. |
Use of an H1 antagonist and a safe steroid to treat eye conditions
|
US6495534B2
(en)
*
|
2000-05-15 |
2002-12-17 |
Pharmacia & Upjohn Spa |
Stabilized aqueous suspensions for parenteral use
|
AU2001262228A1
(en)
*
|
2000-05-15 |
2001-11-26 |
Pharmacia Italia S.P.A. |
Stabilized steroidal suspension
|
AU2001276928A1
(en)
|
2000-07-26 |
2002-02-05 |
Alcon Universal Ltd. |
Improved process for manufacturing compositions containing ciprofloxacin and hydrocortisone
|
WO2002039993A2
(en)
*
|
2000-11-15 |
2002-05-23 |
Chandavarkar Mohan A |
Pharmaceutival preparations comprising corticosteroids and antiinfective agents
|
WO2002040030A1
(en)
*
|
2000-11-16 |
2002-05-23 |
Alcon Manufacturing, Ltd. |
Combination therapy for lowering and controlling intraocular pressure
|
US20030139382A1
(en)
|
2001-09-21 |
2003-07-24 |
Alcon, Inc. |
Method of treating middle ear infections
|
US7001615B1
(en)
|
2001-12-07 |
2006-02-21 |
Alcon, Inc. |
Sustained release ophthalmic, otic and nasal suspension
|
US20090215735A1
(en)
*
|
2002-02-25 |
2009-08-27 |
Alcon, Inc. |
Topical solution formulations containing a corticosteroid and a cyclodextrin
|
US7727549B2
(en)
*
|
2002-07-15 |
2010-06-01 |
Alcon, Inc. |
Pharmaceutical compositions for otic use
|
KR20050059175A
(ko)
*
|
2002-10-18 |
2005-06-17 |
조엘 에스. 에콜스 |
3층 눈물 제제
|
CA2510296A1
(en)
*
|
2002-12-20 |
2004-07-15 |
Control Delivery Systems, Inc. |
Steroid compositions for intraocular use
|
DE602004013420T2
(de)
|
2003-01-21 |
2009-06-04 |
Senju Pharmaceutical Co., Ltd. |
Wässrige flüssige zubereitung mit 2-amino-3-(4-bromobenzoyl)phenylessigsäure
|
US20050069590A1
(en)
*
|
2003-09-30 |
2005-03-31 |
Buehler Gail K. |
Stable suspensions for medicinal dosages
|
US20050095205A1
(en)
*
|
2003-10-31 |
2005-05-05 |
Ramesh Krishnamoorthy |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
US20050197303A1
(en)
*
|
2003-10-31 |
2005-09-08 |
Bausch & Lomb Incorporated |
Combination of loteprednol etabonate and tobramycin for topical ophthalmic use
|
WO2005041980A1
(en)
|
2003-11-03 |
2005-05-12 |
Ivax Corporation |
Soft steroid compositions for use in dry powder inhalers
|
US20050101582A1
(en)
*
|
2003-11-12 |
2005-05-12 |
Allergan, Inc. |
Compositions and methods for treating a posterior segment of an eye
|
US20050250737A1
(en)
*
|
2003-11-12 |
2005-11-10 |
Allergan, Inc. |
Therapeutic ophthalmic compositions containing retinal friendly excipients and related methods
|
US20060141049A1
(en)
*
|
2003-11-12 |
2006-06-29 |
Allergan, Inc. |
Triamcinolone compositions for intravitreal administration to treat ocular conditions
|
US20070224278A1
(en)
|
2003-11-12 |
2007-09-27 |
Lyons Robert T |
Low immunogenicity corticosteroid compositions
|
WO2005053708A1
(ja)
*
|
2003-12-02 |
2005-06-16 |
Senju Pharmaceutical Co., Ltd. |
ロテプレドノールエタボネート水性懸濁液剤
|
PE20050941A1
(es)
|
2003-12-16 |
2005-11-08 |
Nycomed Gmbh |
Suspensiones acuosas de ciclesonida para nebulizacion
|
CN100548271C
(zh)
|
2004-01-20 |
2009-10-14 |
阿勒根公司 |
用于眼部的局部治疗、并优选包括有曲安奈德及透明质酸的组合物
|
US8957034B2
(en)
*
|
2004-01-28 |
2015-02-17 |
Johns Hopkins University |
Drugs and gene carrier particles that rapidly move through mucous barriers
|
US20050182039A1
(en)
*
|
2004-02-13 |
2005-08-18 |
Bausch & Lomb Incorporated |
Use of Loteprednol etabonate for the treatment of dry eye
|
EP1744759B1
(de)
|
2004-03-25 |
2009-09-02 |
Bausch & Lomb Incorporated |
Verwendung von loteprednoletabonat zur behanldung von trockenen augen
|
US20050234018A1
(en)
*
|
2004-04-15 |
2005-10-20 |
Allergan, Inc. |
Drug delivery to the back of the eye
|
US8119154B2
(en)
|
2004-04-30 |
2012-02-21 |
Allergan, Inc. |
Sustained release intraocular implants and related methods
|
US8147865B2
(en)
*
|
2004-04-30 |
2012-04-03 |
Allergan, Inc. |
Steroid-containing sustained release intraocular implants and related methods
|
EP2216026B1
(de)
*
|
2004-07-12 |
2016-04-20 |
Allergan, Inc. |
Ophthalmologische Zusammensetzungen und deren Verwendung zur Behandlung von Augenkrankheiten
|
US8653055B2
(en)
*
|
2004-09-15 |
2014-02-18 |
Teva Animal Health, Inc. |
Corticosteroid having low systemic absorption
|
ES2322200T3
(es)
*
|
2005-05-10 |
2009-06-17 |
Alcon, Inc. |
Formulaciones en suspension que comprenden un principio activo, un tensioactivo poloxamero o meroxapol y un glicol, su uso para la fabricacion de un medicamento para tratar trastornos oftalmicos.
|
DE602006003438D1
(de)
*
|
2005-05-10 |
2008-12-11 |
Alcon Inc |
Ophthalmische suspension aus einem ophthalmischen arzneimittel, einem poloxamin und glykol-tonizitätsanpassenden mittel, verwendung der zusammensetzung zur herstellung eines medikaments zur behandlung von augenerkrankungen
|
EA200800950A1
(ru)
*
|
2005-09-26 |
2008-08-29 |
ПЬЕДМОН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Способы лечения и профилактики среднего отита с применением неионных поверхностно-активных веществ для облегчения трансмембранного введения лекарственного средства в среднее ухо
|
EA200800949A1
(ru)
*
|
2005-09-26 |
2008-08-29 |
ПЬЕДМОН ФАРМАСЬЮТИКАЛЗ ЭлЭлСи |
Способы лечения и профилактики среднего отита посредством химических веществ, способствующих проникновению, для обеспечения трансмембранного поступления лекарственного средства в среднее ухо
|
US20090082321A1
(en)
*
|
2007-09-21 |
2009-03-26 |
Allergan, Inc. |
Steroid containing drug delivery systems
|
KR101430760B1
(ko)
|
2005-10-18 |
2014-08-19 |
알러간, 인코포레이티드 |
후안부 조직으로 선택적으로 침투하는 글루코코르티코이드유도체를 사용한 안과 요법
|
US20070093461A1
(en)
*
|
2005-10-26 |
2007-04-26 |
Bausch & Lomb Incorporated |
Effect of Loteprednol etabonate on vascular dysfunction
|
US20070110812A1
(en)
*
|
2005-11-14 |
2007-05-17 |
Bausch & Lomb Incorporated |
Ophthalmic composition for dry eye therapy
|
US7955632B2
(en)
|
2005-12-07 |
2011-06-07 |
Bayer B.V. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
US20070128251A1
(en)
*
|
2005-12-07 |
2007-06-07 |
Piedmont Pharmaceuticals, Inc. |
Process for manufacturing chewable dosage forms for drug delivery and products thereof
|
WO2007112274A2
(en)
*
|
2006-03-28 |
2007-10-04 |
Javelin Pharmaceuticals, Inc. |
Formulations of low dose non-steroidal anti-inflammatory drugs and beta-cyclodextrin
|
KR20170123724A
(ko)
|
2006-03-28 |
2017-11-08 |
자블린 파머슈티칼스 인코포레이티드 |
저 투여량의 디클로페낙 및 베타-사이클로덱스트린 제형
|
US20070238789A1
(en)
*
|
2006-03-31 |
2007-10-11 |
Chin-Ming Chang |
Prednisolone acetate compositions
|
WO2008002118A1
(es)
*
|
2006-06-27 |
2008-01-03 |
Arturo Jimenez Bayardo |
Una formulación oftálmica en suspensión de etabonato de loteprednol y clorhidrato de ciprofloxacina
|
EP3566692A1
(de)
|
2006-07-21 |
2019-11-13 |
BioDelivery Sciences International, Inc. |
Vorrichtungen zur transmukosalen abgabe mit verbesserter aufnahme
|
WO2008027341A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
WO2008027340A2
(en)
*
|
2006-08-30 |
2008-03-06 |
Merck & Co., Inc. |
Topical ophthalmic formulations
|
CA2663003C
(en)
*
|
2006-09-08 |
2018-02-13 |
Justin Hanes |
Compositions and methods for enhancing transport through mucus
|
TWI415629B
(zh)
*
|
2006-10-26 |
2013-11-21 |
Otsuka Pharma Co Ltd |
含有瑞巴匹特之水性醫藥懸浮物及其製造方法
|
WO2008057360A1
(en)
*
|
2006-11-02 |
2008-05-15 |
Riolan Technologies, Inc. |
Methods of treating an ocular allergy with low dose dexamethasone
|
EP2089035A1
(de)
*
|
2006-11-02 |
2009-08-19 |
Riolan Technologies, Inc. |
Verfahren zur behandlung von blepharitis
|
CN101721714B
(zh)
*
|
2009-12-18 |
2011-12-07 |
重庆莱美药业股份有限公司 |
实体瘤被动靶向性抗癌前药及其制备方法
|
EP2538929A4
(de)
|
2010-02-25 |
2014-07-09 |
Univ Johns Hopkins |
Verzögerte freisetzung von therapiemitteln in einen teil des auges
|
WO2012039979A2
(en)
|
2010-09-10 |
2012-03-29 |
The Johns Hopkins University |
Rapid diffusion of large polymeric nanoparticles in the mammalian brain
|
EP2699229A2
(de)
*
|
2011-04-22 |
2014-02-26 |
Alcon Research, Ltd. |
Ophthalmische zusammensetzung mit einem viskositätsverstärkungssystem mit zwei unterschiedlichen viskositätsverstärkern
|
SG10201610097WA
(en)
|
2011-08-18 |
2017-01-27 |
Biodelivery Sciences Int Inc |
Abuse-resistant mucoadhesive devices for delivery of buprenorphine
|
WO2013043387A1
(en)
|
2011-09-22 |
2013-03-28 |
Bausch & Lomb Incorporated |
Ophthalmic gel compositions
|
US9901539B2
(en)
|
2011-12-21 |
2018-02-27 |
Biodelivery Sciences International, Inc. |
Transmucosal drug delivery devices for use in chronic pain relief
|
EA032552B1
(ru)
|
2012-03-16 |
2019-06-28 |
Дзе Джонс Хопкинс Юниверсити |
Препараты с контролируемым высвобождением для доставки ингибиторов hif-1
|
EP2825207B1
(de)
|
2012-03-16 |
2020-08-19 |
The Johns Hopkins University |
Nichtlineare multiblock-copolymer-arzneimittelkonjugate zur verabreichung von wirkstoffen
|
JP6360040B2
(ja)
|
2012-05-03 |
2018-07-18 |
カラ ファーマシューティカルズ インコーポレイテッド |
粘液浸透性被覆粒子、組成物、医薬組成物、医薬製剤、及びそれらの形成方法
|
MX2014013315A
(es)
*
|
2012-05-03 |
2015-09-10 |
Kala Pharmaceuticals Inc |
Nanoparticulas farmaceuticas que muestran la mejora del transporte de la mucosa.
|
WO2013166385A1
(en)
|
2012-05-03 |
2013-11-07 |
Kala Pharmaceuticals, Inc. |
Pharmaceutical nanoparticles showing improved mucosal transport
|
US11596599B2
(en)
|
2012-05-03 |
2023-03-07 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
US9827191B2
(en)
|
2012-05-03 |
2017-11-28 |
The Johns Hopkins University |
Compositions and methods for ophthalmic and/or other applications
|
JP6392209B2
(ja)
|
2012-05-04 |
2018-09-19 |
ザ・ジョンズ・ホプキンス・ユニバーシティー |
粘液内層を通過する迅速な透過のための脂質ベース薬物キャリア
|
CN103565742A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
氟米龙滴眼液
|
CN103565740A
(zh)
*
|
2012-07-25 |
2014-02-12 |
天津金耀集团有限公司 |
依碳氯替泼诺混悬滴眼液
|
US10568975B2
(en)
|
2013-02-05 |
2020-02-25 |
The Johns Hopkins University |
Nanoparticles for magnetic resonance imaging tracking and methods of making and using thereof
|
EP2956138B1
(de)
|
2013-02-15 |
2022-06-22 |
Kala Pharmaceuticals, Inc. |
Therapeutische verbindungen und verwendungen davon
|
US9688688B2
(en)
|
2013-02-20 |
2017-06-27 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of 4-((4-((4-fluoro-2-methyl-1H-indol-5-yl)oxy)-6-methoxyquinazolin-7-yl)oxy)-1-(2-oxa-7-azaspiro[3.5]nonan-7-yl)butan-1-one and uses thereof
|
AU2014219024B2
(en)
|
2013-02-20 |
2018-04-05 |
KALA BIO, Inc. |
Therapeutic compounds and uses thereof
|
US20150164882A1
(en)
|
2013-07-22 |
2015-06-18 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical compositions for intraocular administration and methods for fabricating thereof
|
US20160279055A1
(en)
|
2013-07-22 |
2016-09-29 |
Imprimis Pharmaceuticals, Inc. |
Pharmaceutical ophthalmic compositions for intraocular administration and methods for fabricating thereof
|
CN108530458A
(zh)
|
2013-11-01 |
2018-09-14 |
卡拉制药公司 |
治疗化合物的结晶形式及其用途
|
US9890173B2
(en)
|
2013-11-01 |
2018-02-13 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
HRP20220793T1
(hr)
*
|
2014-11-07 |
2022-09-16 |
Santen Pharmaceutical Co., Ltd. |
Oftalmološki vodeni sastav
|
WO2016123125A1
(en)
|
2015-01-27 |
2016-08-04 |
The Johns Hopkins University |
Hypotonic hydrogel formulations for enhanced transport of active agents at mucosal surfaces
|
CN106279324A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
CN106279325A
(zh)
*
|
2015-05-27 |
2017-01-04 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106892952A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
一种依碳氯替泼诺新晶型及其制备方法
|
CN106892953A
(zh)
*
|
2015-12-21 |
2017-06-27 |
天津金耀集团有限公司 |
依碳氯替泼诺一水合物及其晶型与制备方法
|
US10336767B2
(en)
|
2016-09-08 |
2019-07-02 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
CA3036340A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
WO2018048747A1
(en)
|
2016-09-08 |
2018-03-15 |
Kala Pharmaceuticals, Inc. |
Crystalline forms of therapeutic compounds and uses thereof
|
US12023344B2
(en)
|
2022-05-25 |
2024-07-02 |
Famygen Life Sciences, Inc. |
Topical otic, ophthalmic, and nasal corticosteroid formulations
|